CollPlant Biotechnologies (CLGN) Q4 2023 earnings summary

Executive summary

• Advanced AbbVie’s dermal filler candidate into clinical development and continued regenerative breast implant development; received a $10 million AbbVie milestone payment in June 2023.

• Closed 2023 with $26.7 million in cash and cash equivalents; a commercial-size breast implant large-animal study was underway, with topline data expected in Q4 2024.

Financial highlights

• FY2023 GAAP revenue was $11.0 million vs. $299,000 in 2022; the increase mainly reflected the $10.0 million AbbVie milestone and $600,000 higher rhCollagen product sales.

• GAAP gross profit was $9.0 million vs. a $101,000 gross loss in 2022; cost of revenue rose to $2.0 million, including $570,000 in inventory write-offs.

• GAAP net loss narrowed to $7.0 million, or $0.62 basic loss per share, from $16.9 million, or $1.53, in 2022.

• Non-GAAP net loss was $5.2 million, or $0.46 per share, vs. $15.2 million, or $1.37, in 2022.

Outlook and guidance

• Topline results from the commercial-size breast implant large-animal study were expected in Q4 2024; the study is intended to support subsequent human studies and commercialization.

• Management cited a strong balance sheet, lean operating structure and partner support as positioning it to pursue aesthetic and regenerative markets in 2024.